• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

ABPI_Incentivising_Antibioics_peter-pryharski-unsplash_landscape
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 23rd February 2022

New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)

OHE opens a series of blog posts on the NICE new health technology evaluation manual. OHE opens a series of blog posts on the NICE new health technology evaluation manual. The blogs will provide a critical discussion around the topics, including…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

OHE opens a series of blog posts on the NICE new health technology evaluation manual.

OHE opens a series of blog posts on the NICE new health technology evaluation manual. The blogs will provide a critical discussion around the topics, including the expected implications of the changes (or lack thereof) in the manual; what is still missing; and what further research is needed.

The National Institute for Health and Care Excellence (NICE) produces evidence-based guidance and advice for health, public health, and social care practitioners. In England and Wales, new health technologies are appraised based on NICE guidance to determine whether they should be made available on the National Health Service. This means that the methods used by NICE to develop that guidance have significant impact on the level and time to patient access to new interventions. NICE guidance on methods for health technology assessment (HTA) is of paramount importance because of its impact on the approach used by other HTA bodies internationally. NICE published the first HTA methods guideline in 2003 and has periodically updated it.

NICE has recently published a new HTA manual for health technology evaluations. The new manual is the result of more than two years of extensive work. In the first stage, NICE identified the evidence that supports a case for change in the methods, followed by a first consultation to identify the most relevant ones. NICE then moved to the analysis of the selected cases for change and set a second consultation to obtain feedback on the proposals for change.

OHE has contributed to the ‘methods review’ journey by producing evidence that is highly relevant to the topics discussed for the review (a few examples are: identify evidence on resource allocation inefficiencies driven by differences in methods and processes between NICE’s HTA programmes; provide a rationale supporting the need of a new outcomes-based value attribution framework for combination regimens in oncology; and clarify the meanings of absolute and proportional shortfall with examples, in early stages of the review). OHE has responded to both consultations, and in a previous blog, we discussed the most notable changes put forward in NICE’s methods first consultation (November – December 2020) and reflected on their potential consequences.

OHE welcomes a number of the changes that address current challenges of treatment evaluation, including the replacement of the end-of-life modifier with a severity modifier; additional flexibility in considering the uncertainty of certain interventions; the inclusion of productivity costs as additional information for the committee whenever such costs may be a critical component of the value of the intervention; broader scope to consider real-world evidence; and the intent to establish a hierarchy of preferred outcome measures to assist those developing technologies.

However, there are several aspects that we believe were not fully or satisfactorily addressed during the review. They are: the reluctance to switch to 1.5% as the discount rate; the continuation in the use of the EQ-5D-3L with utility tariffs dating from 1995; the lack of clear guidance on whether and how to capture health-related quality of life benefits for carers within appraisals; the reluctance of NICE to contemplate the use of the societal perspective as a potential case-for-change; the lack of evidence to set the categories of severity that tag along different values of the severity modifier;  and the lack of clarity on addressing the concept of ‘health inequalities’.

Through this blog, OHE opens a series of blog posts that provide a critical discussion of those topics. The research agenda that will be set as part of the next phase following the publication of the new manual will be critical to delivering an evidence-based change to the current approach.

  • Health Technology Assessment…
  • Value, Affordability, and…
  • NICE

Related Insights

Blog 4
  • Insight
  • October 2022

The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?

Read more
Slide3
  • Insight
  • October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Read more
Sleepio_Adobe_montblanca-e1673970227875
  • Insight
  • May 2022

Sleepio: Lessons from the Frontier of Digital Therapeutics

Read more
3D Isometric Flat Vector Conceptual Illustration of Health Equit
  • Insight
  • April 2022

Let’s talk about (health) inequalities

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!